![Overall survival in endometrial cancer patients according to histologic... | Download Scientific Diagram Overall survival in endometrial cancer patients according to histologic... | Download Scientific Diagram](https://www.researchgate.net/publication/351129993/figure/fig1/AS:11431281102359640@1669461589025/Overall-survival-in-endometrial-cancer-patients-according-to-histologic-subtype.jpg)
Overall survival in endometrial cancer patients according to histologic... | Download Scientific Diagram
![Prognostic Factors for Endometrial and Cervical Cancers of Uterus Treated With Immune-cell Therapy: A Retrospective Study | Anticancer Research Prognostic Factors for Endometrial and Cervical Cancers of Uterus Treated With Immune-cell Therapy: A Retrospective Study | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/40/8/4729/F2.large.jpg)
Prognostic Factors for Endometrial and Cervical Cancers of Uterus Treated With Immune-cell Therapy: A Retrospective Study | Anticancer Research
![Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry | British Journal of Cancer Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-023-02141-0/MediaObjects/41416_2023_2141_Fig1_HTML.png)
Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry | British Journal of Cancer
![Recurrence and survival of patients with stage III endometrial cancer after radical surgery followed by adjuvant chemo- or chemoradiotherapy: a systematic review and meta-analysis | BMC Cancer | Full Text Recurrence and survival of patients with stage III endometrial cancer after radical surgery followed by adjuvant chemo- or chemoradiotherapy: a systematic review and meta-analysis | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-022-10482-x/MediaObjects/12885_2022_10482_Fig4_HTML.png)
Recurrence and survival of patients with stage III endometrial cancer after radical surgery followed by adjuvant chemo- or chemoradiotherapy: a systematic review and meta-analysis | BMC Cancer | Full Text
![A clinically applicable molecular-based classification for endometrial cancers | British Journal of Cancer A clinically applicable molecular-based classification for endometrial cancers | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fbjc.2015.190/MediaObjects/41416_2015_Article_BFbjc2015190_Fig1_HTML.jpg)
A clinically applicable molecular-based classification for endometrial cancers | British Journal of Cancer
![Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification - ScienceDirect Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0090825822001433-ga1.jpg)
Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification - ScienceDirect
![NEJM on X: "In women with advanced endometrial cancer, the median progression-free survival was 7.2 months with lenvatinib plus pembrolizumab and 3.8 months with chemotherapy; the median overall survival was 18.3 months NEJM on X: "In women with advanced endometrial cancer, the median progression-free survival was 7.2 months with lenvatinib plus pembrolizumab and 3.8 months with chemotherapy; the median overall survival was 18.3 months](https://pbs.twimg.com/media/FJf6WueVIAMWHvU.jpg)
NEJM on X: "In women with advanced endometrial cancer, the median progression-free survival was 7.2 months with lenvatinib plus pembrolizumab and 3.8 months with chemotherapy; the median overall survival was 18.3 months
![Preoperative neutrophil:lymphocyte and platelet:lymphocyte ratios predict endometrial cancer survival | British Journal of Cancer Preoperative neutrophil:lymphocyte and platelet:lymphocyte ratios predict endometrial cancer survival | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fbjc.2015.200/MediaObjects/41416_2015_Article_BFbjc2015200_Fig1_HTML.jpg)
Preoperative neutrophil:lymphocyte and platelet:lymphocyte ratios predict endometrial cancer survival | British Journal of Cancer
![Impact of treatment modality on overall survival in women with advanced endometrial cancer: A National Cancer Database analysis - Gynecologic Oncology Impact of treatment modality on overall survival in women with advanced endometrial cancer: A National Cancer Database analysis - Gynecologic Oncology](https://www.gynecologiconcology-online.net/cms/asset/df1047a1-371b-4e49-9cda-931798aa350b/gr1.jpg)
Impact of treatment modality on overall survival in women with advanced endometrial cancer: A National Cancer Database analysis - Gynecologic Oncology
![434 Cytoreductive surgery in stage IV endometrial cancer: A retrospective multicentre cohort study | International Journal of Gynecologic Cancer 434 Cytoreductive surgery in stage IV endometrial cancer: A retrospective multicentre cohort study | International Journal of Gynecologic Cancer](https://ijgc.bmj.com/content/ijgc/31/Suppl_3/A94.3/F1.large.jpg)
434 Cytoreductive surgery in stage IV endometrial cancer: A retrospective multicentre cohort study | International Journal of Gynecologic Cancer
![Adjuvant chemotherapy for stage I high-intermediate risk endometrial carcinoma with lymph-vascular invasion | International Journal of Gynecologic Cancer Adjuvant chemotherapy for stage I high-intermediate risk endometrial carcinoma with lymph-vascular invasion | International Journal of Gynecologic Cancer](https://ijgc.bmj.com/content/ijgc/32/9/1129/F2.large.jpg)
Adjuvant chemotherapy for stage I high-intermediate risk endometrial carcinoma with lymph-vascular invasion | International Journal of Gynecologic Cancer
![Frontiers | Endometrial Cancer Type 2 Incidence and Survival Disparities Within Subsets of the US Black Population Frontiers | Endometrial Cancer Type 2 Incidence and Survival Disparities Within Subsets of the US Black Population](https://www.frontiersin.org/files/Articles/699577/fonc-11-699577-HTML/image_m/fonc-11-699577-g001.jpg)